Functional Foods
Human Milk Oligosaccharides Find a New Brief in Adult Nutrition
Adult digestive-health innovation is shifting the HMO conversation toward ingredient-specific evidence, realistic doses and everyday product economics.
By FTF Editorial Team·October 6, 2026·5 min read
Commercially produced human milk oligosaccharides are being explored beyond infant formula as ingredients for adult digestive-health products. For brands, the opportunity depends on matching the exact ingredient and inclusion level to credible evidence, permitted uses and a sustainable cost per serving.
What happened
Human milk oligosaccharides, or HMOs, are a diverse group of carbohydrates naturally present in human milk. Selected structures, including 2′-fucosyllactose, commonly abbreviated as 2′-FL, and lacto-N-neotetraose, or LNnT, can be produced commercially using microbial fermentation. These manufactured ingredients are not collected from donated human milk, and individual commercially available HMOs do not reproduce the full diversity found in it.
Their development for infant nutrition has also opened a route into adult products. A randomized study published in the British Journal of Nutrition investigated 2′-FL, LNnT and their combination in healthy adults, reporting tolerability and changes in gut microbiota, including increased bifidobacteria. Such findings support further adult research, but they do not establish that every HMO, blend or finished product delivers a noticeable digestive benefit.
Why it matters
For innovation teams, HMOs offer a differentiated route into a digestive-health category already populated by fibers, probiotics and fermented foods. Their appeal rests partly on how particular structures interact with gut microbes. However, an increase in a bacterial group is not automatically evidence of better digestive comfort, improved regularity or another consumer-relevant outcome.
The evidence must follow the ingredient. Results for 2′-FL should not be transferred automatically to LNnT, another HMO or a proprietary blend. Teams need to examine the studied population, dose, duration and endpoints, then distinguish evidence of a microbiome effect from evidence supporting the benefit they intend to communicate.
Market impact
The commercial question is not simply whether an HMO can be added to a supplement, powder or beverage. It is whether a relevant daily amount can fit the serving size, sensory requirements and target price. Gram-level study designs make dose economics especially important: lowering inclusion to meet a cost target can leave a product poorly aligned with the evidence used to justify it.
Regulatory work is equally product-specific. In the European Union, novel-food authorizations specify conditions of use, including applicable food categories and maximum levels. In the United States, FDA GRAS notices and agency responses concern safety under described conditions of use, not approval of digestive-health claims. Neither framework gives a brand blanket permission to use every HMO in every adult format or to promise a health benefit.
Consumer insight
The name itself creates a communication task. Brands should explain that the ingredient is a commercially manufactured carbohydrate with a structure also found in human milk, rather than implying that an adult product contains human milk. Any vegan, allergen or other suitability statement still needs verification against the ingredient specification, production process and finished formulation.
Benefit communication also needs restraint. A consumer looking for less bloating or greater regularity may not regard a microbiome-composition change as meaningful on its own. Positioning should therefore start with a clearly defined need and the evidence relevant to it, rather than relying on infant-nutrition associations to imply broad adult wellness benefits.
Strategic takeaway
Start with the intended adult user and outcome, then select the HMO rather than working backward from an available ingredient. Build an evidence dossier covering identity, manufacturing specifications, adult human studies, tolerability and relevant daily intake. Check the proposed format and claims in each target market before committing to packaging or launch language.
Then pressure-test the business case at the evidence-aligned inclusion level. Compare ingredient cost per daily serving, serving frequency, shelf-life performance and the likely consumer price with established digestive-health alternatives. The strongest proposition is not simply an adult product containing HMOs, but one whose formulation, evidence and claims remain aligned at a price consumers can sustain.
Get the next signal in your inbox.
Daily food industry intelligence — free.
You've reached the end.